SCHEMBL1702608

SCHEMBL1702608

C=Cc1cccc(OC(C)OC)c1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP3A4 P08684 1/20 0.36
TLR2 O60603 1/20 0.35
ERN1 O75460 1/20 0.35
TLR1 Q15399 1/20 0.35
TLR6 Q9Y2C9 1/20 0.35
NFE2L2 Q16236 8/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPT P10636 2/20 0.33
TRPA1 O75762 1/20 0.33
CA12 O43570 2/20 0.32
G6PD P11413 1/20 0.32
HSD17B10 Q99714 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA4 P22748 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1397111 0.87 MEN1 (0.32) KMT2AMEN1ALDH1A1CYP3A4TLR2
SCHEMBL16959513 0.86 MCHR1 (0.37) KMT2AMEN1ALDH1A1CYP3A4TLR2
SCHEMBL7642123 0.85 ALDH1A1 (0.40) KMT2AMEN1ALDH1A1CYP3A4NFE2L2
SCHEMBL1702831 0.84 MEN1 (0.33) KMT2AMEN1ALDH1A1CYP3A4KDM4E
SCHEMBL1397209 0.84 MEN1 (0.31) KMT2AMEN1ALDH1A1CYP3A4
SCHEMBL1397138 0.83 MEN1 (0.30) KMT2AMEN1ALDH1A1CYP3A4
SCHEMBL7990624 0.81 TLR2 (0.46) KMT2AMEN1ALDH1A1CYP3A4TLR2
SCHEMBL16954898 0.81 L3MBTL1 (0.38) KMT2AMEN1ALDH1A1CYP3A4TLR2
SCHEMBL11856226 0.77 TLR2 (0.37) KMT2AMEN1ALDH1A1CYP3A4TLR2
SCHEMBL27602429 0.76 NR2E1 (0.37) KMT2AMEN1ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107229185-B Energy-sensitive composition, cured product, and method for producing cured product 东京应化工业株式会社 2022-04-15 CN disclosed
CN-107207456-B Latent acids and their use 巴斯夫欧洲公司 2021-05-04 CN disclosed
EP-3253735-B1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2021-03-31 EP disclosed
EP-2539316-B1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2019-10-23 EP disclosed
US-9994538-B2 Latent acids and their use BASF SE (DE) 2018-06-12 US disclosed
US-20180009775-A1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2018-01-11 US disclosed
WO-2016124493-A1 LATENT ACIDS AND THEIR USE BASF SE (DE) 2016-08-11 WO disclosed
EP-2007834-B1 SULPHONIUM SALT INITIATORS BASF SE (DE) 2015-11-04 EP disclosed
EP-1595182-B1 HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS BASF SE (DE) 2015-09-30 EP disclosed
EP-1769286-B1 OXIME DERIVATIVES AND THE USE THEROF AS LATENT ACIDS BASF SE (DE) 2015-09-09 EP disclosed
US-20050153244-A1 Sulfonate derivatives and the use thereof as latent acids CIBA SPECIALTY CHEMICALS CORP. 2005-07-14 US disclosed
CN-1628268-A Sulfonic acid derivatives and their use as latent acids CIBA SC HOLDING AG (CH) 2005-06-15 CN disclosed
EP-1392675-B1 SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS CIBA SC HOLDING AG (CH) 2005-02-09 EP disclosed
US-20040209186-A1 Substituted oxime derivatives and the use thereof as latent acids CIBA SPECIALTY CHEMICALS CORP. 2004-10-21 US disclosed
US-20040053158-A1 Onium salts and the use therof as latent acids CIBA SPECIALTY CHEMICALS CORP. 2004-03-18 US disclosed
US-20040002007-A1 Oxime derivatives and the use thereof as latent acids CIBA SPECIALTY CHEMICALS CORP. 2004-01-01 US disclosed
US-6512020-B1 Photosensitive acid-donors in chemically amplified resist formulations. activated by irradiation with actinic electromagnetic radiation and electron beams. CIBA SPECIALTY CHEMICALS CORPORATION 2003-01-28 US disclosed
US-20010036591-A1 Iodonium salts as latent acid donors IGM GROUP B.V. (NL) 2001-11-01 US disclosed
US-6306555-B1 RADIATION-SENSITIVE COMPOSITION COMPRISING CATIONICALLY OR ACID-CATALYTICALLY POLYMERISABLE OR CROSSLINKABLE COMPOUND OR COMPOUND THAT INCREASES ITS SOLUBILITY IN DEVELOPER UNDER ACTION OF ACID, AND AT LEAST ONE DIARYLIODONIUM SALT CIBA SPECIALTY CHEMICALS CORP. 2001-10-23 US disclosed
US-6261738-B1 LATENT CURING CATALYSTS FOR PHOTORESISTS SUCH AS 2,2,2-TRIFLUORO-1-PHENYL-ETHANONE OXIME-O-METHYL SULFONATE CIBA SPECIALTY CHEMICALS CORPORATION 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009775-A1 LATENT ACIDS AND THEIR USE LTA, C1S, C9 KMT2A 2445/4885MEN1 4625/4885ALDH1A1 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.